Checkpoint Immunotherapy: Picking a Winner
- PMID: 27485001
- DOI: 10.1158/2159-8290.CD-16-0694
Checkpoint Immunotherapy: Picking a Winner
Abstract
Robust biomarkers of response that predict which patients will or will not respond to immune checkpoint blockade need to be identified. New data suggest that the presence of an adaptive immune signature in the tumor biopsies of patients with melanoma early on therapy compared to pretreatment can identify responders from nonresponders. Cancer Discov; 6(8); 818-20. ©2016 AACR.See related article by Chen et al., p. 827.
©2016 American Association for Cancer Research.
Comment on
-
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.Cancer Discov. 2016 Aug;6(8):827-37. doi: 10.1158/2159-8290.CD-15-1545. Epub 2016 Jun 14. Cancer Discov. 2016. PMID: 27301722 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
